News Briefs: Monoclonal Antibodies Yield Mixed Results Against Omicron | Dec. 22, 2021

Regeneron Pharmaceuticals’ monoclonal antibody treatment for COVID-19 has “diminished potency” when used against the omicron variant, while AstraZeneca plc’s antibody product “retained neutralizing activity” against the new variant. The antibody treatments remain the standard of care for unvaccinated COVID-19 patients with severe disease. Regeneron emphasized that its treatment is effective against the delta variant. However, omicron has become the dominant variant in recent days: the Associated Press reported 73% of new infections last week were omicron.

© 2022 MMIT

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured_AdobeStock_414656276_Editorial_Use_Only.jpg
January 13

In Blow to PBMs, CMS Floats Reform of Part D Price Concessions

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured_AdobeStock_68809113.jpg
January 13

PBMs Will Face Pressure From Transparency Rules, Startups

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured-Image_Reality-Check_Breast-Cancer.jpg
January 13

Payer Groups Applaud CMS Coverage Decision on Aduhelm

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today